Gh Research Plc (GHRS) Stock Price, Quote & News

Company Profile

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 437 8334

Website: www.ghres.com

Address:

Joshua Dawson House, Dawson Street, Dublin, Ireland

Roaring_Capybara Jan. 13 at 8:58 PM

$GHRS GHRS is in ....... Accumulation mode.

0 · Reply

Angel303 Jan. 13 at 7:42 PM

$GHRS shhes aliveee

0 · Reply

Roaring_Capybara Jan. 12 at 4:13 PM

$GHRS $ATAI ..... Fully loaded up on both.

0 · Reply

Roaring_Capybara Jan. 9 at 2:57 PM

$GHRS Fully RELOADED at 14.85

1 · Reply

Roaring_Capybara Jan. 8 at 8:09 PM

$GHRS Just bought back 1/2 position at 15.58

0 · Reply

McNick Jan. 8 at 10:39 AM

If you had to pick between Phase 2b results $ATAI BLP-003 or $GHRS GH001 ?

1 · Reply

StockScanners Jan. 8 at 7:17 AM

$GHRS keep watch if this holds above 16

0 · Reply

gabrielgriffin72 Jan. 7 at 11:14 PM

$GHRS

0 · Reply

Roaring_Capybara Jan. 7 at 8:36 PM

$GHRS Out at $17.90 (Day-trader rules). Will re-enter soon.

0 · Reply

gabrielgriffin72 Jan. 7 at 6:59 PM

$GHRS beefy

0 · Reply

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

Jan 5, 2026, 7:00 AM EST - 8 days ago

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

Jan 4, 2026, 8:30 AM EST - 9 days ago

GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision

Jan 2, 2026, 4:01 PM EST - 11 days ago

GH Research to Announce IND Status for GH001

Nov 6, 2025, 7:00 AM EST - 2 months ago

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 13, 2025, 2:07 PM EDT - 3 months ago

Depression-Focused GH Research Shares Could See Significant Upside: Analyst

Oct 9, 2025, 7:00 AM EDT - 3 months ago

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

Aug 7, 2025, 7:00 AM EDT - 5 months ago

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 23, 2025, 8:00 AM EDT - 6 months ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Jun 20, 2025, 1:00 PM EDT - 7 months ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

May 15, 2025, 7:00 AM EDT - 8 months ago

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 8, 2025, 7:00 AM EDT - 8 months ago

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

Feb 27, 2025, 7:00 AM EST - 11 months ago

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 4, 2025, 8:52 PM EST - 1 year ago

GH Research Announces Pricing of $150 Million Public Offering

Feb 3, 2025, 4:03 PM EST - 1 year ago

GH Research Announces Proposed Public Offering

Feb 3, 2025, 10:55 AM EST - 1 year ago

Why Is GH Research Stock Trading Higher On Monday?

Feb 3, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Jan 31, 2025, 4:01 PM EST - 1 year ago

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Jan 10, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Nov 14, 2024, 7:00 AM EST - 1 year ago

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:05 AM EDT - 1 year ago

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:00 AM EDT - 1 year ago

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

May 3, 2024, 7:00 AM EDT - 1 year ago

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Feb 29, 2024, 7:00 AM EST - 2 years ago

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Jan 18, 2024, 4:30 PM EST - 2 years ago

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Nov 9, 2023, 4:45 PM EST - 2 years ago

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Sep 29, 2023, 4:45 PM EDT - 2 years ago

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

Aug 23, 2023, 7:00 AM EDT - 2 years ago

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 16, 2023, 11:06 AM EDT - 2 years ago

GH Research: But Toad Venom Is A Controlled Substance

May 11, 2023, 7:30 AM EDT - 2 years ago

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

Mar 2, 2023, 7:00 AM EST - 3 years ago

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

Jan 15, 2023, 11:45 AM EST - 3 years ago

Psychedelic Sunday: Competitive Strategies

ATAI CMPS MNMD

Jan 9, 2023, 7:30 AM EST - 3 years ago

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Nov 10, 2022, 7:05 AM EST - 3 years ago

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Aug 23, 2022, 7:00 AM EDT - 3 years ago

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

May 18, 2022, 7:00 AM EDT - 3 years ago

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

Mar 28, 2022, 7:04 AM EDT - 4 years ago

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Jan 19, 2022, 4:31 PM EST - 4 years ago

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today

Dec 6, 2021, 2:16 PM EST - 4 years ago

GH Research Announces Positive Trial Results For Treatment-Resistant Depression

Dec 6, 2021, 10:15 AM EST - 4 years ago

GH Research Posts Data From Treatment-Resistant Depression Trial

Dec 6, 2021, 7:10 AM EST - 4 years ago

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

Sep 23, 2021, 5:25 PM EDT - 4 years ago

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

Aug 15, 2021, 3:55 AM EDT - 4 years ago

GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry

Jun 25, 2021, 1:23 PM EDT - 4 years ago

7 Companies Go Public Today. What Investors Need to Know.

ELEV MCW TKNO ACXP

Jun 22, 2021, 8:25 PM EDT - 4 years ago

GH Research Seeks $125 Million IPO

Roaring_Capybara Jan. 13 at 8:58 PM

$GHRS GHRS is in ....... Accumulation mode.

0 · Reply

Angel303 Jan. 13 at 7:42 PM

$GHRS shhes aliveee

0 · Reply

Roaring_Capybara Jan. 12 at 4:13 PM

$GHRS $ATAI ..... Fully loaded up on both.

0 · Reply

Roaring_Capybara Jan. 9 at 2:57 PM

$GHRS Fully RELOADED at 14.85

1 · Reply

Roaring_Capybara Jan. 8 at 8:09 PM

$GHRS Just bought back 1/2 position at 15.58

0 · Reply

McNick Jan. 8 at 10:39 AM

If you had to pick between Phase 2b results $ATAI BLP-003 or $GHRS GH001 ?

1 · Reply

StockScanners Jan. 8 at 7:17 AM

$GHRS keep watch if this holds above 16

0 · Reply

gabrielgriffin72 Jan. 7 at 11:14 PM

$GHRS

0 · Reply

Roaring_Capybara Jan. 7 at 8:36 PM

$GHRS Out at $17.90 (Day-trader rules). Will re-enter soon.

0 · Reply

gabrielgriffin72 Jan. 7 at 6:59 PM

$GHRS beefy

0 · Reply

Roaring_Capybara Jan. 7 at 5:25 PM

$GHRS 😁

0 · Reply

cosmosmoon1 Jan. 7 at 5:13 PM

$GHRS fucking Schwab sucks

0 · Reply

Jaashh Jan. 7 at 4:55 PM

$ATAI Ripe for a squeeze... $GHRS up to $1B market cap relative to $ATAI $1.4B. What a deal for a diversified portfolio of psychedelic assets..

0 · Reply

Joby099 Jan. 7 at 9:51 AM

$PLTR $CRME $MNTS $SMXT $GHRS

0 · Reply

Joby099 Jan. 7 at 2:55 AM

$PLTR $CRME $MNTS $SMXT $GHRS

0 · Reply

Roaring_Capybara Jan. 7 at 1:24 AM

$GHRS Just in case you weren't aware, GHRS (as of June 2025 annual report) had ZERO debt and a cash balance of $290 Million. Yearly burn rate of ~$40 Million. This is a golden goose.

0 · Reply

Roaring_Capybara Jan. 6 at 7:31 PM

$GHRS I just opened a 1K share position at $13.64 and plan to add if it goes lower. Price manipulation can be a gift.

1 · Reply

Joby099 Jan. 6 at 7:16 PM

$PLTR $CRME $MNTS $SMXT $GHRS

0 · Reply

OfficialStocktwitsUser Jan. 6 at 6:19 PM

$GHRS RSI: 59.03, MACD: -0.0822 Vol: 0.83, MA20: 13.24, MA50: 13.76 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Arcides Jan. 6 at 4:03 PM

$GHRS -31% from yesterday premarket high, complete garbage..very close to fill the gap

0 · Reply

Joby099 Jan. 6 at 10:17 AM

$PLTR $CRME $MNTS $SMXT $GHRS

0 · Reply

Joby099 Jan. 6 at 12:34 AM

$PLTR $CRME $MNTS $SMXT $GHRS

0 · Reply

Market Cap	791.35M
Revenue (ttm)	0.00
Net Income (ttm)	-38.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	534,100
Avg Vol	489,322
Day's Range	N/A - N/A
Shares Out	52.03M
Stochastic %K	52%
Beta	0.98
Analysts	Strong Sell
Price Target	$32.25